On Jan. 10, 2021, Humanigen announced that they were partnering to make lenzilumab available to hospitalized and hypoxic COVID-19 patients in the event that an Emergency Use Authorization is issued from the FDA and subsequent BLA.

Humanigenﾒs investigational treatment, lenzilumab, a proprietary Humaneeredﾮ anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody, is designed to prevent and treat cytokine storm, a complication considered to be a leading cause of COVID-19 death.